Apr 3, 2024 | Uncategorized
Company is evaluating strategic partners and potential acquirers who could potentially treat 50% more lung nodule patients in the U.S. and save billions of dollars annually in healthcare costs DENVER, April 03, 2024 (GLOBE NEWSWIRE) — Imidex, a pioneering...
Jan 12, 2024 | Uncategorized
IMIDEX is excited to announce that VisiRad XR is one of the first 510(k) cleared medical devices utilizing VertexAI by Google Cloud. We’re grateful for our continued partnership with Google and look forward to working with them into the future to detect lung...
Aug 22, 2023 | Uncategorized
IMIDEX’s CEO Richard Vlasimsky was interviewed by KOA 850AM radio in Denver to discuss the recent FDA clearance of VisiRad XR and how the use of AI tools like VisiRad XR can help identify potential lung cancers. Listen to the segment...
Aug 17, 2023 | Uncategorized
DENVER, Aug. 17, 2023 (GLOBE NEWSWIRE) — IMIDEX, a leader in developing AI-based solutions to address lung cancer, announces that it has received FDA 510(k) clearance for its flagship VisiRad XR product. VisiRad XR is an AI-powered software that analyzes chest...
Mar 7, 2023 | Uncategorized
IMIDEX is thrilled to be selected as a finalist for the InvestU Pitch Event in March 2023. InvestU is a premier angel investment network that leverages Arizona State University’s vast network of resources to create unparalleled value for entrepreneurs, investors, and...
Feb 24, 2023 | Uncategorized
Our partnership with V7 has been instrumental in accelerating us towards our mission to impact lung cancer detection and patient outcomes. Algorithms are only as powerful as the data that drives them, which is why working with V7 has been a game-changer. With their...